Gilead Sales Reps To Promote Virco HIV Resistance Test Services
This article was originally published in The Gray Sheet
Gilead Sciences will leverage its 60-rep U.S. sales force under a collaborative promotional and educational effort with Virco to increase awareness among physicians treating patients with HIV of Virco's phenotypic and genotypic HIV resistance monitoring assays, the firms announced March 7.
You may also be interested in...
Sales reps from ViroLogic, Inc. began calling physicians across the U.S. on Nov. 15 to promote the company's recently commercialized phenotypic HIV drug susceptibility assay, PhenoSense HIV.
Laboratory Corporation of America plans July 20 commercial release of Antivirogram and VircoGen diagnostic testing procedures to evaluate resistance of HIV to antiretroviral drugs via its collaborative partnership with Virco. Antivirogram assesses viral sensitivity to anti-HIV drugs by measuring the ability of the virus to grow in the presence of each drug. The VircoGen genotypic test identifies genetic mutations that can signify drug resistance
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.